KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Liabilities and Shareholders Equity (2017 - 2025)

Historic Liabilities and Shareholders Equity for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $3.6 billion.

  • Amneal Pharmaceuticals' Liabilities and Shareholders Equity rose 401.32% to $3.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $13.9 billion, marking a year-over-year decrease of 7.56%. This contributed to the annual value of $3.5 billion for FY2024, which is 83.15% up from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Liabilities and Shareholders Equity of $3.6 billion as of Q3 2025, which was up 401.32% from $3.4 billion recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Liabilities and Shareholders Equity registered a high of $4.0 billion during Q2 2022, and its lowest value of $3.4 billion during Q1 2025.
  • In the last 5 years, Amneal Pharmaceuticals' Liabilities and Shareholders Equity had a median value of $3.7 billion in 2023 and averaged $3.7 billion.
  • Per our database at Business Quant, Amneal Pharmaceuticals' Liabilities and Shareholders Equity plummeted by 980.98% in 2021 and then soared by 401.32% in 2025.
  • Quarter analysis of 5 years shows Amneal Pharmaceuticals' Liabilities and Shareholders Equity stood at $3.9 billion in 2021, then decreased by 3.56% to $3.8 billion in 2022, then decreased by 8.6% to $3.5 billion in 2023, then increased by 0.83% to $3.5 billion in 2024, then increased by 2.81% to $3.6 billion in 2025.
  • Its last three reported values are $3.6 billion in Q3 2025, $3.4 billion for Q2 2025, and $3.4 billion during Q1 2025.